Adagio Therapeutics announced an update on its lead SARS-CoV-2 monoclonal antibody, ADG20. ADG20 was designed to provide broad and potent neutralizing activity against SARS-CoV-2, including…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.